Failure to provide Bisphosphonates putting breast cancer patients lives at risk

Failure to provide Bisphosphonates putting breast cancer patients lives at risk

Bisphosphonates can reduce the risk of metastases to the bones in cancer patients.

In fact, bisphosphonates reduce the risk of breast cancer moving to the bones by 28 per cent and prevent 18 per cent of women dying from the disease within a decade of diagnosis. 

These were findings in two American studies covered here in Cancer Watch at CANCERactive almost two years ago, yet almost two thirds of breast cancer oncologists in the UK still do not suggest them to their patients, according to an independent charity report.

CANCERactive founder and former Oxford University Biochemist, Chris Woollams, said, “Actually, this is hardly rocket science. The research is very clear.

Breast cancer can progress to the bones, liver or to the other breast. Research is clear: Bisphosphonates strengthen and prevent bone attacks, vitamin K can strengthen the liver and CLA (Conjugated Linoleic Acid) can build up in the other breast and prevent occurrence there.

It’s high time oncologists got to grips with the emerging research. No wonder women are taking their health into their own hands.”

Other research has shown that vitamin K2 is highly preventative of cancer moving to the liver. Normally produced by the gut bacteria in healthy women, its production becomes severely restricted when women are taking gut-bacteria-damaging chemotherapy. (K2 should not be taken if women have blood or cardiovascular problems.)

Go To: 6 Simple steps to keep your bones strong

Also American research has consistently shown the benefits of Conjugated Linoleic Acid in breast cancer tissue.

Vitamin D levels also predict survival times. Unfortunately, 80 per cent of women are low at the time of diagnosis, then levels are further depleted by chemotherapy. There’s good research on this too”, added Woollams who simply believes that people who develop cancer are just not doing the obvious things first. "It is desperately sad, that here is a charity saying two thirds of oncologists don’t know about two research studies on a drug. Well they also don’t know about equally interesting research on other compounds that can keep their patients alive longer." 

"If you are already thinking of supplementing with any of the above you many like to see what Natural Selection has to offer by clicking here". 

2016 Research
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Chris'

Join Chris' NewsletterSignup today for free and be the first to get notified on new updates.